Experimental drug cuts Parkinson's-linked protein up to 60% in early trial

medicalxpress - An experimental drug designed to silence a gene strongly linked to Parkinson's disease has shown encouraging effects in a first-in-human clinical trial, according to a study published in Nature Medicine. The drug, known as BIIB094, targets LRRK2, the most…

AI Summary: An experimental therapeutic cut levels of a Parkinson’s‑linked protein by up to 60% in an early human study, while complementary preclinical work identified a compound that clears toxic Parkinson’s proteins from brain tissue. The twin findings hint at disease‑modifying potential, though meaningful clinical benefit and long‑term safety remain to be demonstrated.

#healthcare #pharmaceuticals #biotech #drugdevelopment #clinicaltrials

Use of psychotropics increases in the early stages of Parkinson's disease

5 wks / medicalxpress

Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals

6 wks / nature / Elisa Menozzi

Brain-on-a-chip reveals how Parkinson's proteins weaken the brain's vascular barrier

6 wks / medicalxpress

Autophagosome-targeting single-domain antibody clears tau in patient-derived neurons and improves motor function in tauopathy mice

6 wks / science / Yixiang Jiang, Amber M. Tetlow, Yan Lin, Changyi Ji, Jack Ader, Klaudia F. Laborc, Adam C. Mar, Ruim

Scientists make Parkinson's drug from plastic in world first

6 wks / medicalxpress

Experimental drug cuts Parkinson's-linked protein up to 60% in early trial

7 wks / medicalxpress

Mysterious 'compound X' clears toxic Parkinson’s proteins from brain

7 wks / newscientist

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Experimental drug cuts Parkinson's-linked protein up to 60% in early trial

Related Stories